GRTX insider transaction filings

Galera Therapeutics, Inc. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen GRTX transaction legs live →

Insider transaction summary — last 90 days

2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
CHANG NANCY T — Director, 10% owner14
FRIEDMAN MICHAEL R. — Director14
Alleva Lawrence M — Director13
Sorensen Mel — President and CEO, Director12
LOKAY KEVIN G — Director11
Sussman Joel F. — Chief Accounting Officer11

Recent Form 4 filings — Galera Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2026-08-054Sorensen Mel — President and CEO, DirectorDisposition to issuer (D): 975 · Disposition to issuer (D): 30,000 (derivative)EDGAR
2026-08-054Alleva Lawrence M — DirectorDisposition to issuer (D): 11 · Disposition to issuer (D): 40 · Disposition to issuer (D): 240 (derivative)EDGAR
2026-08-054CHANG NANCY T — Director, 10% ownerConversion (C): 661,309 · Disposition to issuer (D): 47,434 · Conversion (C): 661.31 (derivative) @ $0 · Disposition to issuer (D): 480 (derivative)EDGAR
2026-08-054LOKAY KEVIN G — DirectorDisposition to issuer (D): 240 (derivative)EDGAR
2026-08-054FRIEDMAN MICHAEL R. — DirectorConversion (C): 2,989,399 · Disposition to issuer (D): 41,631 · Conversion (C): 2,989.40 (derivative) @ $0 · Disposition to issuer (D): 480 (derivative)EDGAR
2026-08-054Sussman Joel F. — Chief Accounting OfficerDisposition to issuer (D): 10,000 (derivative)EDGAR
2026-05-294Emerald Bioventures, LLC — 10% owner
Opler Timothy — 10% owner
Conversion (C): 20,813,818 · Conversion (C): 20,813.82 (derivative)EDGAR
2026-04-094FRIEDMAN MICHAEL R. — DirectorConversion (C): 5,336,870 · Conversion (C): 5,336.87 (derivative) @ $0EDGAR
2026-04-094CHANG NANCY T — Director, 10% ownerConversion (C): 1,180,611 · Conversion (C): 1,180.61 (derivative) @ $0EDGAR
2025-11-244Sorensen Mel — President and CEO, DirectorSale (S): 70,000 @ $0.02EDGAR
2025-05-054Sussman Joel F. — Chief Accounting OfficerGrant/award (A): 2,000,000 (derivative) @ $0EDGAR
2025-05-054Sorensen Mel — President and CEO, DirectorGrant/award (A): 6,000,000 (derivative) @ $0EDGAR
2025-02-264FRIEDMAN MICHAEL R. — DirectorGrant/award (A): 96,000 (derivative) @ $0EDGAR
2025-02-264Alleva Lawrence M — DirectorGrant/award (A): 48,000 (derivative) @ $0EDGAR
2025-02-264LOKAY KEVIN G — DirectorGrant/award (A): 48,000 (derivative) @ $0EDGAR
2025-02-264CHANG NANCY T — Director, 10% ownerGrant/award (A): 96,000 (derivative) @ $0EDGAR
2025-01-024FRIEDMAN MICHAEL R. — DirectorGrant/award (A): 8,326.27 (derivative) @ $0EDGAR
2025-01-024CHANG NANCY T — Director, 10% ownerPurchase (P): 7,644,932 @ $0.07 · Grant/award (A): 1,841.92 (derivative) @ $0EDGAR
2024-08-204Sorensen Mel — President and CEO, DirectorSale (S): 67,015 @ $0.07EDGAR
2024-05-014/ASchneid Yair — 10% ownerPurchase (P): 318,150 @ $0.19 · Purchase (P): 100,000 @ $0.19 · Purchase (P): 68,424 @ $0.20 · Purchase (P): 241,028 @ $0.20 · Purchase (P): 56,900 @ $0.21 · Purchase (P): 50,000 @ $0.21 · +15 moreEDGAR
2024-02-264Schneid Yair — 10% ownerPurchase (P): 150,000 @ $0.18 · Purchase (P): 335,000 @ $0.18 · Purchase (P): 97,402 @ $0.18 · Purchase (P): 25,000 @ $0.20 · Purchase (P): 25,000 @ $0.17 · Purchase (P): 150,000 @ $0.17 · +1 moreEDGAR

Recent 8-K events — Galera Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-048-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-318-K3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-138-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-078-K8.01 — Other EventsEDGAR
2026-05-198-K8.01 — Other EventsEDGAR
2026-05-158-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-118-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-04-148-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
5.01 — Changes in Control of Registrant
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-098-K8.01 — Other EventsEDGAR
2026-04-038-K8.01 — Other EventsEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →